Evidence map›Paper›PMID 41532780›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026

Gray matter microstructure from in vivo diffusion magnetic resonance imaging reflects post mortem neuropathology severity and clinical progression of Alzheimer's disease.

Zaki Alasmar, Cécilia Tremblay, Roqaie Moqadam, Geidy E Serrano, Thomas G Beach, Alireza Atri, Yi Su, Alzheimer's Disease Neuroimaging Initiative, Yashar Zeighami, Mahsa Dadar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Zaki AlasmarCerebral Imaging Centre, Douglas Mental Health University Institute, Montréal, Québec, Canada.ORCID https://orcid.org/0009-0002-1164-6950
Cécilia TremblayCerebral Imaging Centre, Douglas Mental Health University Institute, Montréal, Québec, Canada.
Roqaie MoqadamCerebral Imaging Centre, Douglas Mental Health University Institute, Montréal, Québec, Canada.
Geidy E SerranoBanner Sun Health Research Institute, Sun City, Arizona, USA.
Thomas G BeachBanner Sun Health Research Institute, Sun City, Arizona, USA.
Alireza AtriBanner Sun Health Research Institute, Sun City, Arizona, USA.
Yi SuBanner Alzheimer's Institute, Phoenix, Arizona, USA.
Alzheimer's Disease Neuroimaging Initiative
Yashar ZeighamiCerebral Imaging Centre, Douglas Mental Health University Institute, Montréal, Québec, Canada.
Mahsa DadarCerebral Imaging Centre, Douglas Mental Health University Institute, Montréal, Québec, Canada.

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI ADAM L. BOXER · 2019 to 2026
$120.9M
WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
Early Onset AD Consortium - the LEAD Study (LEADS)U01AG057195 · NIA · INDIANA UNIVERSITY INDIANAPOLIS · PI APOSTOLOVA, LIANA G, CARRILLO, MARIA C · 2018 to 2023
$70.3M
Smartphone-Based "Burst" Cognitive AssessmentsP01AG003991 · NIA · WASHINGTON UNIVERSITY · PI JOHN MORRIS · 1985 to 2026
$69.5M
The Clinical Significance of Incidental White Matter Lesions on MRI Amongst a Diverse Population with Cognitive Complaints (INDEED)U19NS120384 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Kumar B. Rajan · 2020 to 2026
$61.9M
THERAPEUTIC EFFECTS OF INTRA-NASAL INSULIN DETEMIRP50AG005136 · NIA · UNIVERSITY OF WASHINGTON · PI GRABOWSKI, THOMAS J. · 1985 to 2019
$57.2M
The natural history of AB accumulation in preclinical ADP01AG026276 · NIA · WASHINGTON UNIVERSITY · PI MORRIS, JOHN · 2005 to 2025
$49.5M
SUPPLEMENT TO RUSH ALZHEIMERS DISEASE CENTER COREP30AG010161 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1991 to 2020
$49.1M
Satellite Diagnostic and Treatment Clinic CoreP50AG008702 · NIA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI DE JAGER, PHILIP L · 1989 to 2019
$46.3M
National Alzheimer's Coordinating CenterU24AG072122 · NIA · UNIVERSITY OF WASHINGTON · PI STEPHENS, KARI A · 2021 to 2025
$45.8M
TREATMENT OF DEPRESSION IN ALZHEIMER'S DISEASEP50AG005133 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SWEET, ROBERT A · 1985 to 2019
$43.0M
Canadian Institutes of Health Research (CIHR)FRQS, NSERC, CIHR, and Brain CanadaNatural Sciences and Engineering Research Council of Canada (NSERC) Vanier Scholars programNCATS NIH HHS UL1 TR000448NCATS NIH HHS UL1 TR002345NIA NIH HHS P01 AG003991NIA NIH HHS P01 AG026276NIA NIH HHS P20 AG068053NIA NIH HHS P20 AG068077NIA NIH HHS P20 AG068082NIA NIH HHS P30 AG008017NIA NIH HHS P30 AG010129NIA NIH HHS P30 AG010133NIA NIH HHS P30 AG010161NIA NIH HHS P30 AG013846NIA NIH HHS P30 AG013854NIA NIH HHS P30 AG019610NIA NIH HHS P30 AG035982NIA NIH HHS P30 AG053760NIA NIH HHS P30 AG062422NIA NIH HHS P30 AG062428NIA NIH HHS P30 AG062429NIA NIH HHS P30 AG062715NIA NIH HHS P30 AG066444NIA NIH HHS P30 AG066468NIA NIH HHS P30 AG066506NIA NIH HHS P30 AG066507NIA NIH HHS P30 AG066508NIA NIH HHS P30 AG066509NIA NIH HHS P30 AG066511NIA NIH HHS P30 AG066512NIA NIH HHS P30 AG066514NIA NIH HHS P30 AG066515NIA NIH HHS P30 AG066518NIA NIH HHS P30 AG066519NIA NIH HHS P30 AG066530NIA NIH HHS P30 AG072931NIA NIH HHS P30 AG072946NIA NIH HHS P30 AG072947NIA NIH HHS P30 AG072958NIA NIH HHS P30 AG072972NIA NIH HHS P30 AG072976NIA NIH HHS P30 AG072979NIA NIH HHS P30 AG072980NIA NIH HHS P30 AG086401NIA NIH HHS P30 AG086404NIA NIH HHS P50 AG005133NIA NIH HHS P50 AG005136NIA NIH HHS P50 AG005142NIA NIH HHS P50 AG008702NIA NIH HHS P50 AG016573NIA NIH HHS P50 AG016574NIA NIH HHS P50 AG033514NIA NIH HHS P50 AG047266NIA NIH HHS P50 AG047270NIA NIH HHS P50 AG047366NIA NIH HHS R01 AG019771NIA NIH HHS R01 AG021910NIA NIH HHS R01 AG043434NIA NIH HHS R01 AG045571NIA NIH HHS R01 AG052560NIA NIH HHS R01 AG053509NIA NIH HHS R01 AG053993NIA NIH HHS R01 AG054110NIA NIH HHS R01 AG055005NIA NIH HHS R01 AG056031NIA NIH HHS R01 AG056258NIA NIH HHS R01 AG056531NIA NIH HHS R01 AG058724NIA NIH HHS R01 AG061788NIA NIH HHS R01 AG062276NIA NIH HHS R01 AG067781NIA NIH HHS R01 AG068338NIA NIH HHS R01 AG069453NIA NIH HHS R01 AG073235NIA NIH HHS R01 AG077444NIA NIH HHS R35 AG072262NIA NIH HHS R56 AG045571NIA NIH HHS R56 AG074321NIA NIH HHS U01 AG024904NIA NIH HHS U01 AG057195NIA NIH HHS U19 AG063911NIA NIH HHS U19 AG073153NIA NIH HHS U24 AG067418NIA NIH HHS U24 AG072122NIBIB NIH HHS R01 EB009352NIDCD NIH HHS R01 DC008552NIH HHS S10 OD026738NIMH NIH HHS P50 MH071616NINDS NIH HHS P30 NS098577NINDS NIH HHS R01 NS075075NINDS NIH HHS U19 NS120384NINDS NIH HHS U24 NS072026RRD VA I01 RX001534RRD VA I21 RX001381
6 · The paper itself

Abstract

introductionDiffusion-weighted imaging derived mean diffusivity (MD) correlates with Alzheimer's disease (AD) biomarkers, yet its neuropathological correlates remain unclear.

methodsDiffusion-weighted imaging, post mortem neuropathology, and cognitive performance data were obtained from the National Alzheimer's Coordinating Center (N = 97), Alzheimer's Disease Neuroimaging Initiative (N = 21), and Arizona Study of Aging and Neurodegenerative Disorders (N = 15). We examined MD associations with neuropathology, cognitive decline, and expression profiles of AD-implicated genes.

resultsResults revealed two latent variables-one linked to amyloid/tau, the other to vascular pathology-explaining between 70% and 16% of MD-pathology covariance, respectively. Higher MD correlated with worse cognitive performance, both cross-sectionally and up to 16 years prior to death. MD was regionally associated with Thal phase, neuritic plaque density, Braak stage (temporal/limbic), and infarcts (thalamus), and reflected gene expression patterns related to AD. DISCUSSION: In vivo MD captures distinct AD-related pathologies across brain regions and relates to cognitive trajectories and gene expression. HIGHLIGHTS: Diffusion-weighted imaging (DWI) can detect early gray matter microstructural differences in the Alzheimer's disease (AD) continuum. Mean diffusivity (MD) is associated with tau, amyloid and vascular neuropathologies. Thal amyloid phase and Braak tau score correlate with MD in temporal and limbic regions. Multivariate MD scores differentially relate to proteinopathies vs. vascular damage. MD can serve as a non-invasive biomarker to predict post mortem AD neuropathology.

Indexed as

Alzheimer DiseaseDiffusion Magnetic Resonance ImagingGray MatterAgedAged, 80 and overBrainDisease ProgressionFemaleHumansMaleAlzheimer's diseaseamyloid‐βBraak neurofibrillary stagescerebral white matter rarefactioncognitiondiffusion‐weighted MRIgray matter microstructurehistologymean diffusivityneuropathologypost mortemtauThal amyloid phase

Identifiers

PMID41532780
PMCPMC12802076

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.